Arylamine N-Acetyltransferase Is Required for Synthesis of Mycolic Acids and Complex Lipids in Mycobacterium bovis BCG and Represents a Novel Drug Target

Journal of Experimental Medicine

Volumn 199, Issue 9, 2004, Pages 1191-1199

  Bhakta, Sanjib ^a   Besra, Gurdyal S ^c   Upton, Anna M ^a,e   Parish, Tanya ^d   Sholto Douglas Vernon, Carolyn ^a   Gibson, Kevin J C ^c   Knutton, Stuart ^c   Gordon, Siamon ^b   DaSilva, Rosangela P ^b   Anderton, Matthew C ^a   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cell wall; Isoniazid; Macrophage; Metabolism; Mycobacterium tuberculosis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID; LIPID; MYCOLIC ACID; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GENE; BACTERIAL METABOLISM; CELL MEMBRANE PERMEABILITY; DELETION MUTANT; DRUG TARGETING; ENZYME INACTIVATION; LIPID COMPOSITION; MORPHOLOGICAL TRAIT; MOUSE; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; NAT GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; BCG VACCINE; DNA PRIMERS; GENE DELETION; GENES, BACTERIAL; ISONIAZID; LIPIDS; MYCOBACTERIUM BOVIS; MYCOLIC ACIDS; OPEN READING FRAMES; RECOMBINANT PROTEINS;

EID: 2442466919     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20031956     Document Type: Article

References (48)

1. Dye, C., S. Scheele, P. Dolin, V. Pathania, and M.C. Raviglione. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 282:677-686.
2. Bloom, B.R., and C.J. Murray. 1992. Tuberculosis: commentary on a reemergent killer. Science. 257:1055-1064.
3. Bass, J.B., Jr., L.S. Farer, P.C. Hopewell, R. O'Brien, R.F. Jacobs, F. Ruben, D.E. Snider, Jr., and G. Thornton. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am. J. Respir. Crit. Care Med. 149:1359-1374.
4. Mitchison, D.A. 1998. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2:10-15.
5. Liu, J., and H. Nikaido. 1999. A mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids accumulates meromycolates. Proc. Natl. Acad. Sci. USA. 96:4011-4016.
6. Winder, F.G., and P.B. Collins. 1970. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J. Gen. Microbiol. 63:41-48.
7. Wang, L., and K. Takayama. 1972. Relationship between the uptake of isoniazid and its action on in vivo mycolic acid synthesis in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2:438-441.
8. Takayama, K., H.K. Schnoes, E.L. Armstrong, and R.W. Boyle. 1975. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J. Lipid Res. 16:308-317.
9. Wheeler, P.R., and P.M. Anderson. 1996. Determination of the primary target for isoniazid in mycobacterial mycolic acid biosynthesis with Mycobacterium aurum A+. Biochem. J. 318: 451-457.
10. Sacchettini, J.C., and J.S. Blanchard. 1996. The structure and function of the isoniazid target in M. tuberculosis. Res. Microbiol. 147:36-43.
11. Kremer, L., L.G. Dover, H.R. Morbidoni, C. Vilcheze, W.N. Maughan, A. Baulard, S.C. Tu, N. Honore, V. Deretic, J.C. Sacchettini, et al. 2003. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J. Biol. Chem. 278:20547-20554.
12. Quemard, A., C. Lacave, and G. Laneelle. 1991. Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum. Antimicrob. Agents Chemother. 35:1035-1039.
13. Slayden, R.A., and C.E. Barry III. 2000. The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect. 2:659-669.
14. Upton, A.M., A. Mushtaq, T.C. Victor, S.L. Sampson, J. Sandy, D.M. Smith, P.V. van Helden, and E. Sim. 2001. Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol. Microbiol. 42:309-317.
15. Payton, M., R. Auty, R. Delgoda, M. Everett, and E. Sim. 1999. Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance. J. Bacteriol. 181:1343-1347.
16. Payton, M., A. Mushtaq, T.W. Yu, L.J. Wu, J. Sinclair, and E. Sim. 2001. Eubacterial arylamine N-acetyltransferases-identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues. Microbiol. 147:1137-1147.
17. Sim, E., M. Payton, M. Noble, and R. Minchin. 2000. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. Hum. Mol. Genet. 9:2435-2441.
18. Price-Evans, D.A., K.A. Manley, and V.A. McKusick. 1960. Genetic control of isoniazid metabolism in man. Br. Med. J. 2:485-491.
19. Deguchi, T. 1992. Physiology and molecular biology of arylamine N-acetyltransferases. Biomed. Res. 13:231-242.
20. Bernstein, J., W.A. Lott, B.A. Steinberg, and H.L. Yale. 1952. Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. Am. Rev. Tuberc. 65:357-364.
21. Payton, M., C. Gifford, P. Schartau, C. Hagemeier, A. Mushtaq, S. Lucas, K. Pinter, and E. Sim. 2001. Evidence towards the role of arylamine N-acetyltransferase in Mycobacterium smegmatis and development of a specific antiserum against the homologous enzyme of Mycobacterium tuberculosis. Microbiol. 147:3295-3302.
22. Cole, S.T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S.V. Gordon, K. Eiglmeier, S. Gas, C.E. Barry III, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 393:537-544.
23. Garnier, T., K. Eiglmeier, J.C. Camus, N. Medina, H. Mansoor, M. Pryor, S. Duthoy, S. Grondin, C. Lacroix, C. Monsempe, et al. 2003. The complete genome sequence of Mycobacterium bovis. Proc. Natl. Acad. Sci. USA. 100:7877-7882.
24. De Smet, K.A., K.E. Kempsell, A. Gallagher, K. Duncan, and D.B. Young. 1999. Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from Mycobacterium tuberculosis. Microbiol. 145:3177-3184.
25. Parish, T., and N.G. Stoker. 2000. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiol. 146:1969-1975.
26. Roberts, G., D.G. Muttucumaru, and T. Parish. 2003. Control of the acetamidase gene of Mycobacterium smegmatis by multiple regulators. FEMS Microbiol. Lett. 221:131-136.
27. Etienne, G., C. Villeneuve, H. Billman-Jacobe, C. Astarie-Dequeker, M.A. Dupont, and M. Daffe. 2002. The impact of the absence of glycopeptidolipids on the ultrastructure, cell surface and cell wall properties, and phagocytosis of Mycobacterium smegmatis. Microbiol. 148:3089-3100.
28. Klegerman, M.E., P.O. Devadoss, J.L. Garrido, H.R. Reyes, and M.J. Groves. 1996. Chemical and ultrastructural investigations of Mycobacterium bovis BCG: implications for the molecular structure of the mycobacterial cell envelope. FEMS Immunol. Med. Microbiol. 15:213-222.
29. Besra, G.S. 1998. Preparation of cell-wall fractions from mycobacteria. Methods Mol. Biol. 101:91-107.
30. Gordon, S. 1996. The myeloid system. In Weir's Handbook of Experimental Immunology Volume IV. L.A. Herzenberg, D.M. Weir, and C. Blackwell, editors. Blackwell Science, Oxford. 153.1-153.9.
31. Van Hooijdonk, C.A., C.P. Glade, and P.E. Van Erp. 1994. TO-PRO-3 iodide: a novel HeNe laser-excitable DNA stain as an alternative for propidium iodide in multiparameter flow cytometry. Cytometry. 17:185-189.
32. Martinez-Pomares, L., J.A. Mahoney, R. Kaposzta, S.A. Linehan, P.D. Stahl, and S. Gordon. 1998. A functional soluble form of the murine mannose receptor is produced by macrophages in vitro and is present in mouse serum. J. Biol. Chem. 273:23376-23380.
33. Warren, R.M., S.L. Sampson, M. Richardson, G.D. Van Der Spuy, C.J. Lombard, T.C. Victor, and P.D. van Helden. 2000. Mapping of IS6110 flanking regions in clinical isolates of Mycobacterium tuberculosis demonstrates genome plasticity. Mol. Microbiol. 37:1405-1416.
34. Cox, J.S., B. Chen, M. McNeil, and W.R. Jacobs, Jr. 1999. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature. 402:79-83.
35. Moody, D.B., B.B. Reinhold, M.R. Guy, E.M. Beckman, D.E. Frederique, S.T. Furlong, S. Ye, V.N. Reinhold, P.A. Sieling, R.L. Modlin, et al. 1997. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. Science. 278:283-286.
36. Ryll, R., Y. Kumazawa, and I. Yano. 2001. Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids-a review. Microbiol. Immunol. 45:801-811.
37. Nuzzo, I., M. Galdiero, C. Bentivoglio, R. Galdiero, and C. Romano Carratelli. 2002. Apoptosis modulation by mycolic acid, tuberculostearic acid and trehalose 6,6′-dimycolate. J. Infect. 44:229-235.
38. Kana, B.D., E.A. Weinstein, D. Avarbock, S.S. Dawes, H. Rubin, and V. Mizrahi. 2001. Characterization of the cydAB-encoded cytochrome bd oxidase from Mycobacterium smegmatis. J. Bacteriol. 183:7076-7086.
39. Truglio, J.J., K. Theis, Y. Feng, R. Gajda, C. Machutta, P.J. Tonge, and C. Kisker. 2003. Crystal structure of Mycobacterium tuberculosis MenB, a key enzyme in vitamin K2 biosynthesis. J. Biol. Chem. 278:42352-42360.
40. Indrigo, J., R.L. Hunter, Jr., and J.K. Actor. 2002. Influence of trehalose 6,6′-dimycolate (TDM) during mycobacterial infection of bone marrow macrophages. Microbiol. 148:1991-1998.
41. Mushtaq, A., M. Payton, and E. Sim. 2002. The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity. J. Biol. Chem. 277:12175-12181.
42. Sandy, J., A. Mushtaq, A. Kawamura, J. Sinclair, E. Sim, and M. Noble. 2002. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis-an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 318:1071-1083.
43. Slayden, R.A., R.E. Lee, and C.E. Barry III. 2000. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 38:514-525.
44. Larsen, M.H., C. Vilcheze, L. Kremer, G.S. Besra, L. Parsons, M. Salfinger, L. Heifets, M.H. Hazbon, D. Alland, J.C. Sacchettini, et al. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46:453-466.
45. Asselineau, C., J. Asselineau, G. Laneelle, and M.A. Laneelle. 2002. The biosynthesis of mycolic acids by Mycobacteria: current and alternative hypotheses. Prog. Lipid Res. 41:501-523.
46. Barry, C.E., III, R.E. Lee, K. Mdluli, A.E. Sampson, B.G. Schroeder, R.A. Slayden, and Y. Yuan. 1998. Mycolic acids: structure, biosynthesis and physiological functions. Prog. Lipid Res. 37:143-179.
47. Bardou, F., A. Quemard, M.A. Dupont, C. Horn, G. Marchal, and M. Daffe. 1996. Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins. Antimicrob. Agents Chemother. 40:2459-2467.
48. Brooke, E.W., S.G. Davies, A.W. Mulvaney, F. Pompeo, E. Sim, and R.J. Vickers. 2003. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases. Bioorg. Med. Chem. 11:1227-1234.